Stereotaxis to Present New Clinical Evidence and Product Innovations at Heart Rhythm 2015 in Boston
"Our clinical sites continue to generate an abundance of data on the specific advantages of our Niobe® system compared to conventional approaches to cardiac ablation, due to the precise control, high definition mapping and enhanced linear, contiguous lesions that can be achieved during therapy," said
HRS will publish several
Other scientific data to be presented include:
"Feasibility and Safety of a Novel 3-Dimensional RF Energy Monitoring System: Optimizing RF Lesion Formation to Improve AF Ablation Outcomes;"
Mauricio S. Arruda, et al.
"Vdrive™ Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study – The VERSATILE Study in Atrial Fibrillation Ablation;"
Georg Noelker, et al.
On the innovation front,
The core components of
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the
CONTACT: Press Contact:
Martin StammerChief Financial Officer 314-678-6155 Investor Contact: Todd Kehrli/ Jim Byers MKR Group, Inc.323-468-2300